ACYLATED GLUCAGON ANALOGUE, USE THEREOF AND METHODS OF PRODUCING Russian patent published in 2020 - IPC C07K14/605 A61K38/26 A61P3/04 A61P3/06 A61P3/10 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to acylated glucagon analogues and use thereof in medicine. Disclosed is a compound which is a human glucagon receptor and human GLP1 receptor agonist, having formula R¹-H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-carboxyheptadecanoyl]-isoGlu-GSGSGG)-A-R², where R¹ is H, C_1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; and R² represents OH or NH₂; or a pharmaceutically acceptable salt or solvate thereof.

EFFECT: said compound, acting as a double agonist GluGLP-1, promotes faster elimination of excessive adipose tissue, induced persistent body weight loss, improved glycemic control, reducing cardiovascular risk factors, such as high cholesterol, high LDL cholesterol or low HDL-LDL cholesterol ratio; in view of this, disclosed compound can be used in subject, in need thereof, to prevent weight gain, to stimulate body weight loss, to reduce overweight or to treat obesity, including morbid obesity, as well as accompanying diseases and health conditions.

16 cl, 5 tbl, 6 ex